Role of vascular endothelial growth factor in the response to vessel injury  by Victoria Alvarez Arroyo, M. et al.
Role of vascular endothelial growth factor in the response to
vessel injury
M. VICTORIA ALVAREZ ARROYO, CARLOS CARAMELO, M. ANGELES CASTILLA,
FRANCISCO R. GONZA´LEZ PACHECO, OLGA MART´IN, and JAVIER ARIAS
Fundacio´n Jime´nez Dı´az and Hospital Clı´nico, Auto´noma and Complutense Universities, Madrid, Spain
Role of vascular endothelial growth factor in the response to
vessel injury. In the post-embryonic life, physiological angiogen-
esis is tightly controlled. Angiogenesis also occurs in pathological
circumstances such as tumor vessel proliferation, retinal neovas-
cularization and ischemia. The development of collateral circula-
tion is not only not deleterious, but life saving. Other cases such as
neoplastic neovascularization are the basis of the continuous
growth of tumors and metastases, and therefore constitute a
target of therapeutical efforts. Among a list of molecules able to
control angiogenesis, we emphasize the pivotal role of vascular
endothelial growth factor (VEGF). VEGF is a potent mitogen for
endothelial cells, but is devoid of mitogenic activity for other cell
types. VEGF is a polypeptide with four main different isoforms
that are remarkably different in terms of solubility and affinity for
matrix proteins. VEGF interacts with two endothelial cell-specific
tyrosine kinase receptors. The main interest of its study lies in
VEGF’s role in pathological angiogenic processes, where an
increase in the VEGF mRNA expression has been consistently
observed. An interesting example is the up-regulation of VEGF’s
and VEGF receptors’ mRNA in a considerable number of human
tumors and retina, where they have a critical role in the develop-
ment of neovascularization. In recent work in our laboratory, we
have found further potential interactions of VEGF with patho-
physiological mechanisms, namely, the increase in VEGF gene
expression under exposure to reactive oxygen species and the
positive interaction between VEGF and erythropoietin. VEGF
has outstanding possibilities for therapeutic applications aimed at
inhibiting or favoring the development of new vessels.
The present article deals with aspects related to the role
of vascular endothelial growth factor (VEGF) in angiogen-
esis, that is, in vascular proliferation from pre-existing
vessels. This process is typical of the extrauterine life. Data
on vasculogenesis, the generation of vessels from undiffer-
entiated precursors that are typical of embryonic life, are
not included. VEGF has important roles in both vasculo-
genesis and angiogenesis.
In the post-embryonic life, angiogenesis, or new mi-
crovessel growth, is tightly controlled and only works in
conditions of vascular repair after injury or in strictly
regulated mechanisms, for example, in skeletal or uterine
muscular hypertrophy, ovarian cycle or placental develop-
ment. The definition of “injury” broadly spans from the
interruption of vessel continuity by mechanical means to
the lack of nourishment in the vascular occlusion process
and the damage by oxidant metabolites such as reactive
oxygen species. Reactive oxygen species (ROS) denote
compounds that are or that will generate oxygen free
radicals.
Angiogenesis also occurs in pathological circumstances.
Typical examples of angiogenesis occurring in pathological
processes are tumor-associated vessel proliferation, retinal
neovascularization in diabetes mellitus and the collateral
neovascularization appearing in conditions of hypoxia, such
as the action that occurs in ischemic organs. Some of these
cases, for example, the development of collateral circula-
tion, are not only not deletereous but life saving. Others
such as neoplastic neovascularization are the basis of the
continuous growth of tumors and metastases, and therefore
constitute targets for therapeutical efforts.
There are substantial differences between the diverse
angiogenic processes. First, in the endothelial growth in
neoplasms, the process starts from the secretion by the
tumor cells of factors with chemotactic and proliferative
activity on endothelial cells (paracrine mode). Second, in
hypoxia, the neovascularization mechanisms are not suffi-
ciently clear, but the signal factors seem to be produced by
the vascular tissues (autocrine mode). In both cases, the
genetic program of endothelial cells triggers a phenotypic
change to an angiogenic mode. This change implies the
activation of a sequence that includes the production of
proteolytic enzymes, migration, proliferation and, finally, a
return to the previous differentiated state in the new
vessels.
Work done by several researchers all over the world in
the last few years has searched for the regulators of
angiogenesis and has yielded numerous candidates. Table 1
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shows a list of molecules that are able to control angiogen-
esis, which work as positive factors of endothelial and
vascular smooth muscle cell (VSMC) proliferation. Among
all of these agents, we want to highlight the pivotal role of
VEGF. VEGF is a potent mitogen for micro- and macro-
vascular endothelial cells, but is devoid of appreciable
mitogenic activity for other cell types, including those in the
vascular wall, that is, vascular smooth muscle cells and
pericytes. This fact has led to the hypothesis that VEGF
may be a crucial function in the regulation of physiological
and pathological growth of blood vessels.
VEGF is a polypeptide with a relative molecular mass of
45,OOO D. The alternative mRNA splicing of a single gene
implies the existence of four different isoform species of
121, 165, 189 and 206 amino acids (VEGF121, VEGF165,
VEGF189, VEGF206). There are remarkable differences
between these isoforms in terms of solubility and affinity
for matrix proteins containing heparin and heparinoid
residues. VEGF121 has a weakly acid character and behaves
as a soluble protein that fails to bind heparin. The predom-
inant molecular species, VEGF165, is also diffusible, al-
though an important fraction remains bound to the extra-
cellular matrix. The VEGF189 and the VEGF206 are more
basic and bind heparin with greater affinity, and they are
sequestered in the extracellular matrix. Transcripts encod-
ing VEGF121 and VEGF189 are detected in the majority of
cells and tissues expressing VEGF. In contrast, VEGF206
production has only been identified in human and murine
fetal liver cDNA libraries [1].
VEGF is secreted in a regulated fashion by several
cellular types (Table 2). A group of mechanisms have been
found to participate in the regulation of VEGF gene
expression and/or to induce the release of VEGF protein
(Table 3) [1].
VEGF is endowed with a series of biological effects. The
most relevant among them are shown on Table 4. The
actions of VEGF occur through interactions with its endo-
thelial cell-specific tyrosine kinase receptors, i.e., the kinase
domain region (human)/fetal liver kinase (murine) (KDR/
flk-1) and the fms-like tyrosine kinase (flt-1). Both types of
receptors have different signal transduction properties.
KDR/flk-1 produces a strong ligand-dependent tyrosine
kinase phosphorylation and generates a proliferative effect,
Fig. 1. Increased expression of vascular endothelial growth factor
(VEGF) in vascular smooth muscle cells (VSMC) treated with reactive
oxygen species (ROS).
Table 1. Agents with proliferative effects on cells of the vascular wall
Agent EC VSMC
PDGF yes/not yes
aFGF yes yes
bFGF yes yes
EGF yes yes
TGF-a not yes/not
ET-1 yes yes
VEGF yes not
Abbreviations are: PDGF, platelet-derived growth factor; aFGF, acidic
fibroblast growth factor; bFGF, basic fibroblast growth factor; EGF,
endothelial growth factor; TGF-a, transforming growth factor-a; ET-1,
endothelin-1; EC; endothelial cells; VSMC, vascular smooth muscle cells.
Table 2. Cellular species which produce VEGF
Tumors
Follicular cells of the anterior pituitary
Vascular smooth muscle cells
Mesangial cells
Monocytes
Fibroblasts
Cheratinocytes
Osteoblasts
Astrocytes
Table 3. Stimulatory mechanisms of VEGF expression and/or
production
Hypoxia
AGEs
IL-1
IL-6
IGF-I
ROS
TGF-b
Angiotensin II
Adenosine
Transitional metals
Abbreviations are: AGEs, advanced glycosylation end products; IL-1,
interleukin-1; IL-6, interleukin-6; IGF-1, insulin like growth factor I; EGF,
epidermal growth factor; TGF, transforming growth factor; ROS, reactive
oxygen species.
Table 4. Vascular endothelial growth factor: Biological effects
Endothelial cells mitogenesis
Increase in vascular permeability
Induction of the expression of the serine proteases
Induction of the expression of the interstitial collagenase
Induction of vasodilation and nitric oxide production
Stimulation of hexoses transport
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while flt-1 has a weak VEGF-dependent tyrosine phosphor-
ylation on endothelial cells and does not appear to generate
mitogenic signals [1]. Even though total or partial expres-
sion of VEGF receptors has been recently described in
other cellular types such as osteoblasts or mesangial cells,
their role(s) is not yet defined.
The main interest in the study of VEGF lies in its role in
pathological angiogenesis. In these pathological angiogenic
processes, an increase in the VEGF mRNA expression has
been observed, opening the possibility of relevant thera-
peutic applications. An interesting example is the up-
regulation of VEGF and VEGF receptors mRNA in a
considerable number of human tumors. The available
information indicates that VEGF has a critical role in the
development of tumor-associated neovascularization [2–4].
Another important pathological condition involving VEGF
is the neovascularization of diabetic proliferative retinopa-
thy [5].
In recent work in our laboratory, we have found further
potential interactions of VEGF with potential pathophysi-
ological mechanisms. As an example, a marked increase in
the VEGF gene expression and in the release of VEGF
protein was observed in human vascular smooth muscle
cells treated with reactive oxygen species (Fig. 1). Further-
more, the existence of a positive interaction between
VEGF and the erythroid stimulating hormone, erythropoi-
etin, was detected in endothelial cells treated with recom-
binant human erythropoietin. This interaction involved a
higher proliferative response to VEGF and a potentiated
increase in the VEGF-induced intracellular calcium tran-
sient. A possible explanation for these results is related to
an additional finding, namely, the increased expression of
the KDR/flk-1 and flt-1 receptor genes in endothelial cells
treated with recombinant human erythropoietin (Fig. 2)
[6].
The therapeutic applications of VEGF are basically
related to the attempt of increasing or decreasing tissue
VEGF concentration. This has been done by means of
direct administration, gene transfer with cDNA encoding
VEGF or inhibition by antisense oligonucleotides in cases
of ocular neovascularization. These approaches included,
for example, the development of collateral vessels in the
hind limb ischemia and stent endothelization for revascu-
larization procedures [7, 8]. It is rather predictable that
these new approaches will reach a more extensive field of
application in the near future.
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